niacinamide and gne-617

niacinamide has been researched along with gne-617 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cosino, E; Dragovich, PS; Jackson, P; LaCap, JA; Lee, LB; Liang, X; Liederer, BM; Ly, J; Nannini, M; O'Brien, T; Oeh, J; Ogasawara, A; Qin, A; Sampath, D; Vanderbilt, A; Williams, S; Xiao, Y; Yang, L	1

Other Studies

1 other study(ies) available for niacinamide and gne-617

Article	Year
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytokines; Drug Synergism; Female; Gene Expression; Heterocyclic Compounds, 2-Ring; Humans; Mice; Mice, Nude; NAD; Niacin; Niacinamide; Nicotinamide Phosphoribosyltransferase; Pentosyltransferases; Sulfones; Xenograft Model Antitumor Assays	2013

Article

Year

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:12

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytokines; Drug Synergism; Female; Gene Expression; Heterocyclic Compounds, 2-Ring; Humans; Mice; Mice, Nude; NAD; Niacin; Niacinamide; Nicotinamide Phosphoribosyltransferase; Pentosyltransferases; Sulfones; Xenograft Model Antitumor Assays

2013